Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Benoit You"'
Autor:
Benoit You, Vasudha Sehgal, Balakrishna Hosmane, Xin Huang, Peter J. Ansell, Minh H. Dinh, Katherine Bell-McGuinn, Xizhi Luo, Gini F. Fleming, Michael Friedlander, Michael A. Bookman, Kathleen N. Moore, Karina D. Steffensen, Robert L. Coleman, Elizabeth M. Swisher
Publikováno v:
Journal of Clinical Oncology. 41:107-116
PURPOSE In VELIA trial, veliparib combined with carboplatin-paclitaxel, followed by maintenance (veliparib-throughout) was associated with improved progression-free survival (PFS) compared with carboplatin-paclitaxel alone in patients with high-grade
Autor:
Benoit You, Christopher Purdy, Larry J. Copeland, Elizabeth M. Swisher, Michael A. Bookman, Gini Fleming, Robert Coleman, Leslie M. Randall, Krishnansu S. Tewari, Bradley J. Monk, Robert S. Mannel, Joan L. Walker, Fabio Cappuccini, David Cohn, Mahvish Muzaffar, David Mutch, Andrea Wahner-Hendrickson, Lainie Martin, Olivier Colomban, Robert A. Burger
Publikováno v:
Journal of Clinical Oncology. 40:3965-3974
PURPOSE In patients with high-grade ovarian cancer, predictors of bevacizumab efficacy in first-line setting are needed. In the ICON-7 trial, a poor tumor intrinsic chemosensitivity (defined by unfavorable modeled cancer antigen-125 [CA-125] ELIMinat
Publikováno v:
JCO Clinical Cancer Informatics.
PURPOSE An international meta-analysis identified a group of patients with advanced epithelial ovarian cancer (EOC) with a very poor survival because of two unfavorable features: (1) a poor chemosensitivity defined by an unfavorable modeled CA-125 EL
Autor:
Pascal Pujol, Kévin Yauy, Amandine Coffy, Nicolas Duforet-Frebourg, Sana Gabteni, Jean-Pierre Daurès, Frédérique Penault-Llorca, Frédéric Thomas, Kevin Hughes, Clare Turnbull, Virginie Galibert, Chloé Rideau, Laetitia Collet, Benoit You, David Geneviève, Nicolas Philippe
Publikováno v:
Journal of Clinical Oncology. 40:551-551
Background: PARP inhibitor (PARPi) agents can improve progression-free survival of patients with breast cancer (BC) who carry a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant (gBRCA1/2) in both the metastatic and adjuvant setting. Th
Autor:
Alexandra Leary, Elise Deluche, Laure Favier, Xavier Paoletti, Laura Mansi, Olivier Tredan, Lauriane Eberst, Thibault De La Motte Rouge, Florence Joly, Alain Lortholary, Benoit You, Frederik Marmé, Toon Van Gorp, Anne Floquet, Jean-Sebastien Frenel
Publikováno v:
Journal of Clinical Oncology. 40:TPS5614-TPS5614
TPS5614 Background: Besides PARP inhibitors and bevacizumab, there are no approved maintenance therapies after platinum based chemotherapy for patients with a platinum sensitive relapsed epithelial ovarian cancer (OC). Immune checkpoint inhibitors (I
Autor:
Benoit You, Christopher Purdy, Elizabeth M. Swisher, Michael A. Bookman, Gini F. Fleming, Robert L. Coleman, Leslie M. Randall, Krishnansu Sujata Tewari, Bradley J. Monk, Robert S. Mannel, Joan L. Walker, Fabio Cappuccini, Larry J. Copeland, Mahvish Muzaffar, David Gardner Mutch, Andrea Elisabeth Wahner Hendrickson, Lainie P. Martin, Olivier Colomban, Robert Allen Burger
Publikováno v:
Journal of Clinical Oncology. 40:5553-5553
5553 Background: In patients with high-grade ovarian cancer in first-line setting, predictive factors of bevacizumab efficacy are needed, for selecting patients. In ICON-7 trial, a poor tumor intrisic chemosensitivity (defined by unfavorable modeled
Publikováno v:
Journal of Clinical Oncology. 38:4350-4351
Autor:
Cristina Saura, Yasuaki Sagara, Jillian Cathcart, Fabrice Andre, Eriko Tokunaga, Yali Liu, Peter Hall, Ian E. Krop, Benoit You, Sara A. Hurvitz, Cynthia Osborne, Yeon Hee Park, Toshinari Yamashita, Guy Jerusalem, Shanu Modi, Caleb Lee, Xavier Alberto Andrade Gonzalez, Christophe Perrin, Sung Bae Kim
Publikováno v:
Journal of Clinical Oncology. 39:526-526
526 Background: Patients (pts) with HER2+ metastatic breast cancer (mBC) are at high risk of developing brain metastases (BMs), and treatment options are limited once BMs occur. T-DXd is an antibody-drug conjugate composed of an anti-HER2 antibody, a
Autor:
Benoit You, Fanny Pommeret, François Ghiringhelli, Aurélien Marabelle, Corinne Balleyguier, Rastilav Bahleda, Christophe Massard, Judith Michels, Caroline Brard, Jean-Sebastien Frenel, Anne Floquet, Sophie Broutin, Emeline Colomba, Lauriane Eberst, Alexandra Leary, Patricia Pautier, Catherine Genestie
Publikováno v:
Journal of Clinical Oncology. 39:5522-5522
5522 Background: There is a medical unmet need for effective treatments in platinum resistant ovarian cancer patients. We assessed the safety and efficacy of a combination of pembrolizumab with bevacizumab and pegylated liposomal doxorubicin (PLD). M
Autor:
Gwenaelle Garin, Isabelle Ray-Coquard, Benoit You, Virginie Marcel, Michel Fabbro, Camille Chakiba, Antoine Arnaud, Patricia Pautier, Cyril Abdeddaim, Laurence Lancry Lecomte, Jean-Jacques Diaz, Jean-Sebastien Frenel, Pierre-Etienne Heudel, Paule Augereau, David Pérol, Fernando Bazan, Isabelle Treilleux, Cécile Dalban, Florence Joly, Annick Chevalier
Publikováno v:
Journal of Clinical Oncology. 39:5507-5507
5507 Background: Endometrial carcinoma is generally hormone dependent and aromatase inhibitors are used in routine practice before or after 1st line chemotherapy (CT) for HR positive patients. Deregulation of the Pi3K-Akt-mTOR signaling pathway is ob